FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours por rosponso:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ferrante Karen Jean					2. Issuer Name and Ticker or Trading Symbol Cogent Biosciences, Inc. [ COGT ]					(Che	eck all applic  Directo	able) r	Person(s) to Iss 10% C	wner	
	GENT BIO	SCIENCES, INC			3. Date of Earliest Transaction (Month/Day/Year) 10/01/2021							Officer below)	(give title	Other ( below)	specify
200 CAMBRIDGE PARK DRIVE, SUITE 2500					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) CAMBR	IDGE M	ΙA	02140								1 '	X Form fi	led by More t	Reporting Perso	
(City)	(S	tate)	(Zip)												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned														
1. Title of Security (Instr. 3)  2. Transar Date (Month/Date)					Execution Date,		Code (Instr. 5)			5. Amour Securitie Beneficia Owned F	s Forn ally (D) o ollowing (I) (Ir	. Ownership form: Direct D) or Indirect I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
								Code V	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	ion(s)		(111341. 4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Cod	nsaction le (Instr.			6. Date Exer Expiration D (Month/Day/	ate	e Amount of		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Coo	e V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$8.54	10/01/2021		A		2,385 <sup>(1)</sup>		(2)	10/01/2031	Common Stock	2,385	\$5.0317	2,385	D	

## Explanation of Responses:

- 1. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant.
- 2. This option is fully vested at time of grant.

## Remarks:

/s/ Ryan Murr, Attorney-in-Fact 10/05/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.